Silexion Therapeutics Corp · NASDAQ:SLXN
Silexion Therapeutics — Investor Presentation (February 2026)
34 slides from Silexion Therapeutics's investor presentation, Feb 3, 2026
Slide 1: Silencing Oncogenes at the Level of Gene Expression
Silencing Oncogenes at the Level of Gene Expression Nasdaq: SLXN Company Presentation | February 2026
Slide 2: Forward-Looking Statement
Forward-Looking Statement The statements contained in this presentation that are not purely historical are forward-looking statements. Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strateg
Slide 3: Transforming treatment in historically undruggable cancers
Transforming treatment in historically “undruggable” cancers by tackling the driver of poor outcomes Lead product targets the most common oncogenic driver in human cancers, mutated KRAS gene Our technology, siRNA, isolates the oncogene, resulting in shutting down the cancer driving processes First g
Slide 4: Agenda
Agenda 4 Market and unmet need Our technology Advantages and differentiation of our technology / product First generation siRNA Phase 2 clinical results and preclinical results SIL204 SIL204 Phase 2/3 design SIL204 development plan and milestones achieved Patent protection for SIL204
Slide 5: Prevalent Cancers with KRAS Mutation we Target
5 1. Lee, J.K. et al. NPJ Precis Oncol. 2022;6(1):91.; 2. Hirshberg Foundation for Pancreatic Cancer Research. Pancreatic cancer Facts. https://pancreatic.org/pancreatic-cancer/pancreatic-cancer-facts. Pancreatic Ductal Adenocarcinoma (PDAC) Colorectal Cancer (CRC) Non-squamous Non-Small-Cell Lung C
Slide 6: Types and Relative Prevalence of Pancreatic Cancer
BRPC=borderline resectable pancreatic cancer; LAPC = locally advanced pancreatic cancer. Gemenetzis G, et al. Ann Surg. 2019;270(2):340-347; Kleeff J, et al. Nat Rev Dis Primers. 2016;2:16022. Local Metastatic 15-25% Resectable + BRPC ~30 LAPC ~50% Metastatic ~75% liver 6 Types and Relative Prevalen
Slide 7: Unmet Needs in Pancreatic Cancer (PC)
Unmet Needs in Pancreatic Cancer (PC) 1. National Cancer Institute. Cancer Stat Facts: Pancreatic Cancer. https://seer.cancer.gov/statfacts/html/pancreas.html. 2. Cancers 2021, 13(18), 4724; https://doi.org/10.3390/cancers13184724. 3. Gemenetzis G, et al. Ann Surg. 2019;270(2):340-347. 4. Alagesan,
Slide 8: Our Technology: Lead Product SIL204
8 Our Technology Lead Product: SIL204 First-in-class, isoform selective, pan KRAS silencer, stable siRNA with targeted delivery system Targets both the active and inactive forms of KRAS x
Slide 9: Dual Administration of SIL204
Dual Administration of SIL204 Designed to Effectively Treat the Two Distinct Processes of the Disease: Primary Tumor and Metastases Intratumoral (endoscopic) SIL204 Targets Primary pancreatic tumor overcoming it’s ECM barrier Systemic (s.c.) SIL204 Targets cancer cells shedding from primary tumor wi
Slide 10: Our Technology: LDL targeting mechanism
10 Our Technology SIL204 binds to LDLs to high extent and carries the SIL204 systemically Pancreatic cancer cells have significantly higher LDL receptors than health pancreatic cells Enriched uptake by cancer cells compared to healthy Difference even more significant in metastatic pancreatic cells L
Slide 11: Advantages and Differentiation
11 Advantages and Differentiation SIL204 positioned to become the most advanced RNA-interfering oncology product
Slide 12: LODER (First generation siRNA) Phase Clinical Trial Data Results
LODER (First generation siRNA) Phase 2 Clinical Trial Data Results
Slide 13: Reduction in tumor size: Cohorts 1+2
Reduction in tumor size: Cohorts 1+2 First-Generation Mutant KRAS RNA Silencer (Loder) Led to Robust RECIST* Antitumor Activity in mutant KRAS-Driven Locally Advanced Pancreatic Cancer LAPC=locally advanced pancreatic cancer. *Response Evaluation Criteria in Solid Tumors. Overall response rate was c
Slide 14: Loder Patients Had 9.3 Months Improvement in Overall Survival
Cohort 1 LAPC KRAS_G12V or G12D Patients Treated with Loder Had 9.3 Months Improvement in Overall Survival 14 * SoC (Control) OS consistent with recent trials for LAPC (Gemenetzis G, et al. Ann Surg. 2019;270(2):340-347). Hazard ratio (HR)=0.59, (95% CI, 0.18, 1.96, p=0.39) Time to death is slower,
Slide 15: Safety From First Generation Loder Trial
Safety From First Generation Loder Trial 15 Brinda Alagesan, B. et al. (2026) A Phase 2 Trial of an Extended-release siRNA Implant Targeting KRAS G12D/V in Locally Advanced Pancreatic Cancer. Clinical Cancer Research (in press) siG12D-LODER was generally well tolerated (includes intratumoral Loder r
Slide 16: SIL204 Second Generation Results
SIL204 Second Generation Results
Slide 17: SIL204 Knockdown of mRNA Transcript and KRAS Protein
17 SIL204 Knockdown of mRNA Transcript and Corresponding KRAS Protein Transfection with lipofectamine PK59 human tumor line G12D mutation Analysis at 72 hrs for mRNA and protein **** = p value ＜0.0001
Slide 18: SIL204 (Second Generation siRNA)
SIL204 (Second Generation siRNA)
Slide 19: SIL204 Broad Inhibition Across Human KRAS Mutations
SIL204 Highly Effective with Broad Inhibition Across Human KRAS Mutations at Sub-nanomolar Concentrations SIL204 maintains and expands the silencing activity of first generation siG12DLoder 19 Model is a co-transfection setup where human KRAS is transfected in mouse Hepa1-6 cells with Dual-Glo repor
Slide 20: SIL204 Inhibits Growth of Human Tumor Cell Lines
SIL204 Inhibits Growth Human Tumor Cell Lines from Various Cancers with G12x and Q61x Mutations 20 Cell line KRAS mutation subtype IC50 (ng/mL) IC90 (nM) IC90 (ng/mL) A427 (Lung) G12D 537 70 1,079 PK59 (Panc) G12D 1,059 163 2,496 GP2D (Colon) G12D 445 56 852 HS766T (Panc) Q61H 476 124 1,907 AVG 613
Slide 21: In Silico Stability Shows High Specificity of SIL204
In Silico Thermodynamic Stability of Potential Duplexes Shows High Specificity of SIL204 for (K)RAS and Not (H)RAS/(N)RAS and No Off-target Binding SIL204 binding to KRAS G12V strong (-31.8 kcal/mole) No Off-Target Active Anti-sense Binding indicating low risk for side effects. No effect on regulato
Slide 22: Intratumor SIL204 Reduced Tumor Volume and Growth
Intratumor SIL204 Significantly Reduced Tumor Volume and Growth While Increasing Tumor Necrosis (cell death) in Human Pancreatic Cancer Xenograft 22 *p<0.05 ; ***p<0.0005 S.C. = sub cutaneous tumor, intratumor SIL204-SL administration. Day 1: Capan-1 (KRAS G12V) luciferase cells were xenografted to
Slide 23: SIL204 Remains at Substantial Levels for >56 Days in Rats
SIL204 Remains at Substantial Levels for >56 Days in Target Tissues in Rats 23 PK profiles of SIL204 after a single s.c. administration were determined in Sprague Dawley rats using a LC-MS/MS analytical method, in the plasma and after collection from kidney, liver, and skin. IC50/90 data from inhibi
Slide 24: Subcutaneous SIL204 in Orthotopic Metastatic Pancreatic Mouse Model
Subcutaneous SIL204 in Orthotopic Metastatic Pancreatic Mouse Model 24 Tumors from Human tumor cell line Panc-1 harboring KRAS G12D mutation-luciferase Response analysis total bioluminescence. 30% and 50% decrease considered positive at Day 14. 30%=RECIST criteria Responder analysis Control High dos
Slide 25: SIL204 Synergistic with Pancreatic Cancer Chemotherapy
SIL204’s Anti-Tumor Activity Synergistic with Pancreatic Cancer Chemotherapy * p<0.05, ***p<0.0005 Human pancreatic cell line Panc-1 (G12D) 25 *** *
Slide 26: Toxicology
Toxicology Extended single-dose GLP toxicity studies completed in 2 relevant species, aligned with ICH S9 guidance for oncology and confirmed by regulatory agency for initiation of Phase 2/3 clinical trial Established safety margins of up to 11-fold over the clinical starting dose. SIL204 was well-t
Slide 27: SIL204 Phase 2/3 Clinical Trial
SIl204 Phase 2/3 Clinical Trial Segment 1: Phase 2/3 safety run-in Initiation Q2 2026 Expected completion Q4 2026 Segment 2: Phase 2 expansion Initiation Q4 2026 Segment 3: Phase 3 confirmatory Initiation Q3 2028 SIL204 administered intratumorally and systemically as an integrated treatment regimen
Slide 28: SIL204 Phase 2/3 Development Plan and Milestones Achieved
SIl204 Phase 2/3 Development Plan and Milestones Achieved GMP API for Segment 1 manufactured, Segment 2 GMP manufacturing ongoing GMP formulation selected, manufacturing in process Toxicology for Segment 1 completed, for Segment 2/3 later in 2026 Scientific Advice from national European authority, w
Slide 29: Strategic Collaboration for SIL204 GMP Clinical Supply
Strategic Collaboration for SIL204 GMP Clinical Supply with Leading European Manufacturers Collaboration to leverage Catalent and Axolabs’ experience in formulation development and manufacturing biologicals to further enhance SIL204's therapeutic potential through improved stability, bioavailability
Slide 30: Intellectual Property Protection
Intellectual Property Protection Exclusivity can be extended under country-specific regulatory-based extension rules. Submissions Term Entered national Phase world wide, SIL-204 as a composition and for use in treatment of pancreatic and other cancers (following successful USPTO review of PCT) U.S.
Slide 31: Highly Experienced Leadership Team
Highly Experienced Leadership Team Ilan Hadar, MBA Chairman and Chief Executive Officer Over 25 years of multinational executive managerial and corporate experience with pharmaceutical and high-tech companies. CEO PainReform (“PRFX”), CFO Foamix Pharmaceuticals Inc. (Currently “VYNE”) Mitchell Shirv
Slide 32: World-Renowned Expert Scientific Advisory Board
World-Renowned Expert Scientific Advisory Board Eileen M. O'Reilly, MD Memorial Sloan Kettering, NY, NY Winthrop Rockefeller Endowed Chair of Medical Oncology; Co-Director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research; Section Head, Hepatopancreatobi Hana Algul, MD
Slide 33: SIL204 First in class siRNA targeting KRAS mutation
SIL204First in class siRNA targeting KRAS mutation Phase 2/3 initiation for locally advance pancreatic cancer to be initiated Q2/2026 Isoform selective, pan KRAS silencer, stable siRNA with targeted delivery system Pipeline for additional cancers including CRC First generation (Loder) showed trend f
Slide 34: Thank You
Thank You Nasdaq: SLXN Ilan Hadar Chairman & Chief Executive Officer email: ihadar@silexion.com Dr. Mitchell Shirvan Chief Scientific and Development Officer email: mshirvan@silexion.com Mirit Horenshtein Hadar, CPA Chief Financial Officer email: mirit@silexion.com
Silexion Therapeutics — Investor Presentation (February 2026) on 6ix